Abstracts tagged "Renal"

Abstract Number: 2407 • ACR Convergence 2024
Clinical Utility of Repeat Renal Biopsies in Lupus Nephritis: The NIH Chronicity Index at First Biopsy Predicts Future End Stage Renal Disease in a Large South Asian Cohort of SLE
Rudrarpan Chatterjee¹, Neeraja Vijayan², Durga P Misra³, Vikas Agarwal³, Able Lawrence⁴ and Amita Aggarwal⁵, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁴SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Renal biopsy remains a cornerstone of management of lupus nephritis. Repeat renal biopsies after therapy help prognosticate renal outcomes. We sought to describe the…
Abstract Number: 1356 • ACR Convergence 2024
Association Between Vascular Inflammation and Kidney Function in Patients with Rheumatoid Arthritis: Secondary Analysis of TARGET Trial
Sho Fukui¹, Ahmed Tawakol², Wolfgang Winkelmayer³, Leah Santacroce⁴, Jon Giles⁵, Katherine Liao⁴, Joan Bathon⁶ and Daniel Solomon⁷, ¹Brigham and Women's Hospital, Brookline, MA, ²Massachusetts General Hospital/Harvard Medical School, Boston, MA, ³Baylor College of Medicine, Houston, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Cedars Sinai Medical Center, Los Angeles, CA, ⁶Columbia University, NEW YORK, NY, ⁷Brigham and Women's Hospital, Newton, MA
Background/Purpose: Kidney dysfunction is a common complication in patients with rheumatoid arthritis (RA). More severe disease activity is associated with a larger decline in the…
Abstract Number: 2441 • ACR Convergence 2024
Investigating Kidney Disease Risks in Systemic Sclerosis (SSc) – Effects of Proton Pump Inhibitors (PPI): Retrospective Analysis
Irakli Tskhakaia and Arthur Lau, Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: Systemic Sclerosis (SSc) patients often experience gastrointestinal complications, frequently managed with proton pump inhibitors (PPIs). Despite evidence of PPI-related chronic kidney disease (CKD) risk in…
Abstract Number: 1117 • ACR Convergence 2023
Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis
Chio Yokose¹, Gregory Challener², Baijun Zhou², Natalie McCormick², Sruthi Tanikella², Kila Panchot², Minna Kohler³, Janeth Yinh², Yuqing Zhang⁴, David Bates⁵, James Januzzi², Meghan Sise², Deborah Wexler² and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…
Abstract Number: 2380 • ACR Convergence 2023
Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data
Chan-Bum Choi¹, Jung-Min Shin², Nayeon Choi³ and Soorack Ryu³, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, South Korea, ³Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare systemic autoimmune disease with varying reports of incidence rates and clinical manifestations. Renal involvement is one of the…
Abstract Number: 1125 • ACR Convergence 2023
A Rheumatologic Clinical Profile of the VEXAS Syndrome: Results from a Survey Conducted Among Rheumatologic Units of 126 Hospitals Across Spain
Marta López I Gómez¹, Paula García Escudero², Marta López³, Berta Magallanes López⁴, Meritxell Salles Lizarzaburu⁵, Beatriz Frade Sosa⁶, Elena Riera⁷, Ernesto Trallero Araguás⁸, MARIA ELVIRA DIEZ ALVAREZ⁹, Francisco Javier Toyos Sáenz de Miera¹⁰, Alicia Garcia Dorta¹¹, José Ángel Hernández Beriain¹², Marta Ibáñez Martínez¹³, carolina Merino¹⁴, PALOMA VELA¹⁵, Ana Victoria Orenes Vera¹⁶, Diego Dios Santos¹⁷, Jose Alberto Miranda Filloy¹⁸, Clara García Belando¹⁹, María Rodríguez Laguna²⁰, Ignacio Vázquez²¹, Joaquin Belzunegui²², Judit Font²³, Carlos de Miguel Sánchez²⁴, Zuriñe Ortiz de Zárate Caballero²⁵ and Jaime Calvo Alén²⁶, ¹Hospital Universitario de Araba, Pamplona, Spain, ²Hospital Universitario Araba, Bilbao, Spain, ³Hospital Universitario Arava, Pamplona, Spain, ⁴Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵C. H. de Manresa - Fundació Althaia, Barcelona, Spain, ⁶Hospital Clínic de Barcelona, Barcelona, Spain, ⁷H. U. Mútua Terrasa, Barcelona, Spain, ⁸Department of Rheumatology, Hospital Universitario Vall d'Hebron, Barcelona, Spain, ⁹Rheumatology, Hospital Universitario de León, León, Spain, ¹⁰Hospital Virgen Macarena, Sevilla, Spain, ¹¹Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹²Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ¹³C. A. U. de Salamanca, Salamanca, Spain, ¹⁴Rheumatology Department Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, ¹⁵Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹⁶H. Arnau de Vilanova, Valencia, Spain, ¹⁷Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁸C. H. U. Lucus Augusti, Lugo, Spain, ¹⁹Hospital Los Arcos del Mar Menor, Murcia, Spain, ²⁰H. Clínico San Carlos, Madrid, Spain, ²¹H. U. Dr. Peset, Valencia, Spain, ²²H. C. Alto Deba, Donostia, Spain, ²³Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ²⁴Hospital Universitario de Araba, Hematology, VItoria, Spain, ²⁵Hospital Universitario de Araba, Internal Medicine, Vitoria, Spain, ²⁶Hospital Universitario Araba, Vitoria, Spain
Background/Purpose: The newly described VEXAS syndrome is a very heterogenous disease with rheumatologic and hematologic manifestations, caused by somatic mutations affecting UBA1 gene, that still…
Abstract Number: 2382 • ACR Convergence 2023
Relapse of Patients with ANCA-associated Vasculitis Who Are on Dialysis
Yeo-Jin Lee¹, Hansun Song², Wook Jang Seo³, Jinseok Kim⁴, Soo-Min Ahn¹, Ji-Seon Oh⁵, Yong-Gil Kim², Chang-Keun Lee¹, Bin Yoo¹ and Seokchan Hong¹, ¹Asan Medical Center, Seoul, South Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ³Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea, ⁴Department of Rheumatology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju-si, Jeju-do, South Korea, La Jolla, CA, South Korea, ⁵Department of Information Medicine, Big Data Research Center, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, South Korea
Background/Purpose: It is known that disease activity of ANCA-associated vasculitis (AAV) is decreased after dialysis. However, most studies have been conducted on Caucasians, and factors…
Abstract Number: 1394 • ACR Convergence 2023
Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study
Bon San Koo¹, Subin Hwang¹, Ye-Jee Kim², Soo Min Ahn² and Wook Jang Seo³, ¹Inje University Seoul Paik Hospital, Seoul, South Korea, ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ³Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed as first-line treatment for symptom relief and inflammation reduction in patients with ankylosing spondylitis (AS). However, long-term…
Abstract Number: 2493 • ACR Convergence 2023
Renal Prognosis of Dialysis-dependent Patients at Baseline in ANCA-associated Vasculitis
Maxime Vignac¹, Dorian Nezam², François Grolleau³, Pauline Morel⁴, Dimitri Titeca-Beauport⁵, Stanislas Faguer⁶, alexandre Karras⁷, Justine Solignac⁸, Noémie Jourde-Chiche⁹, Francois Maurier¹⁰, Hamza Sakhi¹, Khalil El Karoui¹, Rafik Mesbah¹¹, Pierre Louis Carron¹², Vincent Audard¹, Didier Ducloux¹³, Romain Paule¹⁴, Jean-François Augusto¹⁵, Julien Aniort¹⁶, Aurélien Tiple¹⁶, Cédric Rafat¹, Xavier Puéchal¹⁷, Pierre Gobert¹⁸, Catherine Hanrotel¹⁹, Stéphane Bally²⁰, Nihal Martis²¹, Cécile-Audrey Durel²², Pascal Godmer²³, Aurélie Hummel²⁴, François Perrin²⁵, Antoine Néel²⁶, Claire De Moreuil²⁷, Tiphaine Goulenok²⁸, Dominique Guerrot²⁹, Aurelie Foucher³⁰, Alban DEROUX¹², Loic Guillevin³¹, Alexis REGENT³², Raphaël Porcher³ and Benjamin Terrier³³, ¹APHP, Paris, France, ²CH du Havre, Havre, France, ³Université Paris Cité, Paris, France, ⁴AURA Paris Plaisance, Paris, France, ⁵CHU Amiens, Amiens, France, ⁶CHU Toulouse, Toulouse, France, ⁷HEGP - APHP, Paris, France, ⁸APHM, Marseille, France, ⁹AP-HM, Marseille, France, ¹⁰Hôpitaux privés de Metz, Vaux / Frankreich, France, ¹¹Boulogne Hospital (CH), Boulogne, France, ¹²CHU de Grenoble, Grenoble, France, ¹³CHU de Besançon, Besançon, France, ¹⁴Hôpital Foch, Paris, France, ¹⁵CHU d'Angers, Angers, France, ¹⁶CHU de Clermont Ferrand, Clermont Ferrand, France, ¹⁷National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ¹⁸Clinique Rhône Durance, Avignon, France, ¹⁹CHU Brest, Brest, France, ²⁰CH Métropole Savoie, Chambery, France, ²¹CHU de Nice, Nice, France, ²²CHU Lyon, Lyon, France, ²³CH Bretagne Atlantique, Vannes, France, ²⁴CHU Necker, Paris, France, ²⁵CH Saint Nazaire, Saint Nazaire, France, ²⁶CHU de Nantes, Nantes, France, ²⁷CHU de Brest, Brest, France, ²⁸Assistance Publique Hopitaux de Paris, Paris, France, ²⁹CHU Rouen, Rouen, France, ³⁰CHU de la Réunion, Saint pierre, France, ³¹University Paris Descartes, Paris, France, ³²CHU Cochin, Université Paris Cité, Paris, France, ³³Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Renal involvement in ANCA-associated vasculitides (AAV) is an organ- and life-threatening manifestation and therefore an important prognostic factor. However, the identification of predictive factors…
Abstract Number: 1480 • ACR Convergence 2023
Demographic and Clinical Characteristics of Patients with LN: A Multicenter Study from the Gulf Region
Jamal Al-Saleh¹, Faisal Elbadawi¹, Rajaie Namas², Samar Al-Emadi³, Khalid A. Alnaqbi⁴, Humaid A. Al-Wahshi⁵, Amjad Alkadi⁶, Suad Hannawi⁷, Mohamed Hamouda⁸, Averyan Vasylyev⁸, Arwa Al-Shujairi⁸, Reem Al-Jayyousi⁹ and Munther Khamashta⁸, ¹Dubai Hospital, Department of Rheumatology, Dubai, United Arab Emirates, ²Cleveland Clinic Abu Dhabi, Department of Rheumatology, Abu Dhabi, United Arab Emirates, ³Hamad Medical Corporation, Department of Rheumatology, Doha, Qatar, ⁴Tawam Hospital, Department of Rheumatology, Al Ain, United Arab Emirates, ⁵The Royal Hospital, Department of Rheumatology, Muscat, Oman, ⁶Ministry of Health, Kuwait, Kuwait, ⁷Kuwait Hospital, Department of Rheumatology, Dubai, United Arab Emirates, ⁸GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, ⁹Mohamed Bin Rashid University of Medicine and Health Sciences, College of Medicine, Dubai, United Arab Emirates, and Mediclinic Parkview, Dubai, United Arab Emirates
Background/Purpose: Data from limited studies of LN in the Gulf region suggest that LN manifests more severely in this region than in Caucasian populations, yet…
Abstract Number: 0186 • ACR Convergence 2023
Retention in Rheumatology Care and on Hydroxychloroquine and SLE Outcomes by Neighborhood Disadvantage: A Medicare Cohort Study of Acute Care and Kidney Failure
Christie M. Bartels¹, Ang Yu², Felix Elwert², Andrea Gilmore-Bykovskyi³, W. Ryan Powell⁴, Shivani Garg⁵ and Amy J. Kind⁴, ¹University of Wisconsin, School of Medicine and Public Health, Madison, WI, ²Department of Sociology, University of Wisconsin, Madison, WI, ³Berbee Walsh Department of Emergency Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Center for Health Disparities Research, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Gaps in systemic lupus (SLE) care are believed to contribute to higher kidney failure (ESKD), acute care use, mortality, and disease damage in US…
Abstract Number: 1490 • ACR Convergence 2023
Early Experience with SGLT2i in Systemic Lupus Erythematosus
Michelle Petri¹, Daniel Goldman¹, Andrea Fava² and Larry Magder³, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of the systemic lupus erythematosus (SLE) patients. It remains an independent risk factor for mortality, with deaths…
Abstract Number: 0243 • ACR Convergence 2023
Decreased Incidence of Gout After Kidney Transplant over the Last Decade: An Analysis from a Large Academic Renal Transplant Center
Nishah Panchani¹, Angelo Gaffo² and Vineeta Kumar³, ¹Tinsley Harrison Internal Medicine Residency Program, University of Alabama at Birmingham, Arlington, TX, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL; Birmingham VA Medical Center, Birmingham, AL, ³Division of Nephrology/Transplant, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout has been associated with high rates of morbidity and mortality in kidney transplant (KT) patients with increased bone destruction and associated cardiovascular and…
Abstract Number: 1511 • ACR Convergence 2023
B-Cell Recovery in a Randomized Controlled Trial of B-Cell Depletion with Obinutuzumab for the Treatment of Proliferative Lupus Nephritis
Ed Vital¹, Dario Roccatello², David Black³, Rhian Jacob-Moffatt⁴, Cary M. Looney⁵, Elsa Martins⁵, Huiyan (Ashley) Mao³, Thomas Schindler⁶, Himanshi Seghal⁵, Jay Garg⁷, Jorge Ross Terres⁷ and Richard Furie⁸, ¹University of Leeds, Leeds, United Kingdom, ²University of Torino, Torino, Italy, ³Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁴F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom, ⁵F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁶F. Hoffmann-La Roche Ltd, Basle, Switzerland, ⁷Genentech, Inc., South San Francisco, CA, ⁸Northwell Health, Manhasset, NY
Background/Purpose: Patients with LN who received obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, with standard-of-care (MMF) immunosuppression (Phase II NOBILITY; NCT02550652; PMID 34615636) showed…
Abstract Number: 0544 • ACR Convergence 2023
Autoantibodies to dsDNA and Associated Proteins: Association with Proteinuria and Lupus Nephritis
Ranjan Gupta¹, Amita Aggarwal², Avinash Jain³, Liza Rajasekhar⁴, Chengappa Kavadichanda⁵, Vineeta Shobha⁶, Ashish J Mathew⁷, Parasar Ghosh⁸, Bidyut Das⁹ and Manish Rathi¹⁰, ¹All India Institute of Medical Sciences, New Delhi, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ³SMS Medical College, Lucknow, India, ⁴Nizam's Institute of Medical Sciences, Madhapur, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁶St. John's National Academy of Health Science, Bangalore, India, ⁷Christian Medical College, Vellore, India, ⁸Govt of West Bengal, Kolkata, India, ⁹SCB medical college, Cuttack, India, ¹⁰Postgraduate Institute of Medical education and Research, Chandigarh, India
Background/Purpose: Anti-dsDNA antibodies (ADA) are traditionally measured by ELISA and are associated with Lupus nephritis (LN). Testing by immunoline assay (IL) provides additional information on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].